Dren Bio, Inc.
Biotechnology ResearchCalifornia, United States51-200 Employees
Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.
Strategic Partnership Dren Bio, Inc. recently secured a $3 billion agreement with Novartis Pharma to develop bispecific antibodies for cancer, indicating a substantial sales opportunity through collaboration and joint research and development efforts.
Financial Injection With recent equity investments totaling $175 million from Novartis, including a $25 million upfront payment, Dren Bio has the financial resources to explore new sales avenues and expand its offerings, presenting a window for potential sales pitches and partnerships.
Elite Hiring Dren Bio strengthened its leadership team by appointing Dr. Amit Mehta as the Chief Operating Officer and Chief Business Officer, showcasing a strategic move towards bolstering business operations and potentially opening doors to new sales channels and market expansion.
Top Talent Acquisition The departure of Dr. Will as the Chief Medical Officer and subsequent move to Autolus signifies a potential opportunity for Dren Bio to attract top talent for key roles, fostering new partnerships, and leveraging industry expertise for enhanced sales strategies.
Innovative Product Development Dren Bio's development of novel Targeted Myeloid engagers for cancer, in collaboration with Novartis, presents a cutting-edge solution that can create buzz in the market and attract interest from potential buyers looking for innovative treatment options.
Dren Bio, Inc. uses 8 technology products and services including cdnjs, Font Awesome, Ionicons, and more. Explore Dren Bio, Inc.'s tech stack below.
Dren Bio, Inc. Email Formats | Percentage |
FLast@drenbio.com | 50% |
FLast@drenbio.com | 50% |
Biotechnology ResearchCalifornia, United States51-200 Employees
Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.
Dren Bio, Inc. has raised a total of $25M of funding over 5 rounds. Their latest funding round was raised on Jul 24, 2024 in the amount of $25M.
Dren Bio, Inc.'s revenue is in the range of $10M
Dren Bio, Inc. has raised a total of $25M of funding over 5 rounds. Their latest funding round was raised on Jul 24, 2024 in the amount of $25M.
Dren Bio, Inc.'s revenue is in the range of $10M